From: Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies
Characteristics | Melbourne Collaborative Cohort Study | European Prospective Investigation into Cancer and Nutrition (Italy) | European Prospective Investigation into Cancer and Nutrition (IARC) | Prostate, Lung, Colorectal and Ovarian Screening Trial |
---|---|---|---|---|
Acronym | MCCS | EPIC-Italy | EPIC-IARC | PLCO |
Reference | (17) | (18) | (19) | – |
Location | Australia | Italy | Germany, Greece, Italy, Spain, The Netherlands, and the UK | US |
Methylation array used | HM450K | HM450K | HM450K | EPIC |
Number of subjects, n | ||||
 Controls (N = 1926) | 409 | 248 | 423 | 805 |
 Cases (N = 1703) | 409 | 248 | 423 | 583 |
Age at blood draw (years), mean (SD) | 56.7 (7.9) | 52.2 (7.2) | 52.2 (9.0) | 62.2 (5.2) |
Time from blood draw to diagnosis in cases | ||||
 Median (IQR) | 7.7 (4.4., 11.1) | 6.55 (2.5, 10.6) | 7.7 (5.0, 10.3) | 8.4 (5.6, 10.5) |
 Average (SD) | 7.6 (3.9) | 6.7 (4.4) | 7.5 (3.2) | 7.9 (3.5) |
ER status, n (%) | ||||
 Positive | 297 (72.6) | 147 (59.3) | 350 (82.7) | 411 (70.5) |
 Negative | 103 (25.2) | 30 (12.0) | 73 (17.3) | 78 (12.9) |
Stage†, n (%) | ||||
 Early | 246 (60.1) | 71 (28.6) | 207 (48.9) | 337 (57.8) |
 Late | 141 (34.5) | 40 (16.1) | 95 (22.5) | 183 (31.4) |